CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994. CSPC is a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng Mainland Healthcare Index", "Hang Seng Stock Connect Hong Kong Index" and "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index".
CSPC has three major business segments including innovative drugs, common generic drugs and bulk drugs. The Group focuses on the manufacturing, researching and marketing of medicines and pharmaceutical related products. The Group has nearly 1,000 finished drugs products including antibiotics, cardio-cerebrovascular drugs, antipyretic analgesic drugs, digestive system drugs, oncology drugs and traditional Chinese medicine. Of which, "NBP", "Oulaining", "Xuanning". "Duomeisu", "Jinyouli" and "Nuolining" are the bestselling innovative drugs products of the Group in China. Bulk drugs products include antibiotics, vitamin C and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China.
According to the World Brand Lab (one of the leading independent consultancy of brand valuation in the world), the "CSPC" brand was ranked among the "Top 500 Most Valuable Brands in China" for eleven consecutive years since 2004.
With regards to corporate social responsibility activities, CSPC has taken an important role in supporting social welfare charities. For example, CSPC has participated in charity campaigns regarding SARS, the Indonesian tsunami, the Sichuan earthquake, the Yushu earthquake, children with serious illness and other volunteer services etc. CSPC is strongly aware of community needs and is fully committed to continuous contributions to the society.